FDA action on tap for Pfizer's rare disease drug

Pfizer ($PFE) will soon learn whether the FDA will allow the drug giant to sell a drug called tafamidis meglumine for a rare genetic disease called TTR-FAP. The FDA action date is set for June 16, or tomorrow, Bloomberg reported, but word from the agency could come today. For Pfizer, the decision has bearing on the growth of the company's specialty drug business, which includes treatments for rare diseases. A question is whether the FDA will side with its non-agency advisers, who have endorsed approval of the drug, or with a staff assessment that cited insufficient evidence to support approval. Article

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.